Best Lentiviral Vector CDMOs by Signal Score

← All Lentiviral CDMOs Best Clean FDA History Commercial Scale
Region: USA Europe Asia
10
CDMOs tracked
10
Fully scored
8
With FDA records
27
FDA inspections
76
EMA/MHRA GMP certs

Lentiviral vectors are the workhorse of ex vivo gene therapy, used to engineer T cells for CAR-T and to modify hematopoietic stem cells. Because the vector ends up in patient-bound cells, manufacturers carry the regulatory weight of a critical starting material under full GMP.

Choosing a lentiviral vector CDMO comes down to BSL-2 containment, a mature suspension or adherent platform, robust analytics (titer, potency, RCL testing), and a clean regulatory record. The rankings below score each CDMO on FDA inspection history, GMP certification, clinical-program activity, and capacity signals.

FDA inspection outcomes across these CDMOs: 13 NAI (no action), 14 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: UNITED KINGDOM (33), United States (24), Denmark (18), France (7), Germany (5).

Last updated 2026-08-22. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
 83.1 97.9 6 insp · 10 GMP Available 2 programs
2
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
 80.6 99.9 2 insp · 23 GMP Available 2 programs
3
Lonza
Basel, Switzerland
 78.2 95.1 2 insp · 8 GMP — 1 programs
4
OX
Oxford Biomedica
Oxford, United Kingdom
 77.1 100.0 0 insp · 13 GMP Available 7 programs
5
CI
Cincinnati Children's Vector Production Facility
Cincinnati, OH
 75.2 100.0 1 insp · 0 GMP — 1 programs
6
NR
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
 73.4 97.7 1 insp · 0 GMP Available 9 programs
7
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
 91.7 98.7 8 insp · 11 GMP Limited 0 programs
8
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
 88.0 100.0 0 insp · 3 GMP — 0 programs
9
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
 86.9 100.0 3 insp · 0 GMP Available 0 programs
10
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
 81.0 98.8 4 insp · 8 GMP — 0 programs
How we score CDMOs →

What to evaluate in a Lentiviral Vector CDMO

Containment & biosafety
Lentivirus requires BSL-2 manufacturing with segregated suites and validated decontamination. Confirm the site's containment design and replication-competent lentivirus (RCL) testing strategy.
Process platform maturity
Suspension culture scales more cleanly than adherent for larger batches. Ask whether the platform is serum-free and how it performs at your target dose and patient volume.
Analytics & potency
Titer, infectivity, and potency assays drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both are shown in the rankings above and on each profile.

Lentiviral Vector CDMOs — Frequently Asked Questions

Who are the top Lentiviral Vector CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Lentiviral Vector CDMOs include Thermo Fisher Scientific, AGC Biologics, Lonza. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Lentiviral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 8 Lentiviral Vector CDMOs with FDA inspection records and 76 EMA/MHRA GMP certificates across the group.
What should I look for in a lentiviral vector CDMO?
Prioritize BSL-2 containment, a mature suspension platform, qualified titer/potency/RCL assays, and a clean FDA and EMA/MHRA record. Match capacity to your dose and patient volume, and confirm tech-transfer support.
How is lentiviral vector manufacturing different from AAV?
Lentivirus integrates into the host genome and is produced under BSL-2 with RCL testing, typically for ex vivo cell engineering. AAV is non-integrating, made at higher volumes, and used mainly for in vivo gene therapy.
Related modalities
Cell Therapy CDMOs CAR-T CDMOs AAV / Gene Therapy CDMOs
Other Modalities
AAV CAR-T Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Cell & Gene Therapy